Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients

European Journal of Clinical Pharmacology

Volumn 70, Issue 12, 2014, Pages 1433-1441

  Misiak, Błazej ^a   Frydecka, Dorota ^a   Łaczmański, Łukasz ^a   ͆le¸zak, Ryszard ^a   Kiejna, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

First episode schizophrenia; Homocysteine; Olanzapine; One carbon metabolism; Risperidone; Second generation antipsychotics

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CHLORPROMAZINE; CHOLESTEROL; CREATININE; CYANOCOBALAMIN; FOLIC ACID; GLUCOSE; HALOPERIDOL; HOMOCYSTEINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL; CARBON; GLUCOSE BLOOD LEVEL;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BODY MASS; CARBON METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; FOLIC ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MENTAL PATIENT; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MONOTHERAPY; ONE CARBON METABOLISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX RATIO; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; ANALYSIS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; SEX DIFFERENCE; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; CARBON; CHOLESTEROL; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; RISPERIDONE; SCHIZOPHRENIA; SEX FACTORS; TRIGLYCERIDES; VITAMIN B 12; YOUNG ADULT;

EID: 84922089070     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1762-2     Document Type: Article

References (56)

1. Laursen TM, Nordentoft M, Mortensen PB (2014) Excess early mortality in schizophrenia. Annu Rev Clin Psychol 10:425-448. doi:10.1146/annurev-clinpsy-032813-153657
2. Bener A, Al-Hamaq AO, Dafeeah EE (2014) A twofold risk of metabolic syndrome in a sample of patients with schizophrenia: do consanguinity and family history increase risk? Diabetes Met ab Syndr 8(1):24-29. doi:10.1016/j.dsx.2013.10.003
3. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK (2010) Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diabetes Rep 10(3):209-216. doi:10.1007/s11892-010-0112-8
4. Misiak B, Frydecka D, Slezak R, Piotrowski P, Kiejna A (2014) Elevated homocysteine level in first-episode schizophrenia patients - the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab Brain Dis. doi:10.1007/s11011-014-9534-3
5. Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N, Zhang X, Yang F, Tan Y (2013) Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res 210(3):825-829. doi:10.1016/j.psychres.2013.08.056
6. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160(2):284-289
7. Wu X, Huang Z, Wu R, Zhong Z, Wei Q, Wang H, Diao F, Wang J, Zheng L, Zhao J, Zhang J (2013) The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr Res 150(1):157-162. doi:10.1016/j.schres.2013.07.051
8. Garcia-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martinez-Cengotitabengoa M, Pina-Camacho L, Rodriguez-Jimenez R, Saiz PA, Castro C, Lafuente A, Santabarbara J, Gonzalez-Pinto A, Parellada M, Rubio G, Garcia-Portilla MP, Mico JA, Bernardo M, Leza JC (2013) Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. doi:10.1093/schbul/sbt001
9. Ayesa-Arriola R, Perez-Iglesias R, Rodriguez-Sanchez JM, Mata I, Gomez-Ruiz E, Garcia-Unzueta M, Martinez-Garcia O, Tabares-Seisdedos R, Vazquez-Barquero JL, Crespo-Facorro B (2012) Homocysteine and cognition in first-episode psychosis patients. Eur Arch Psychiatry Clin Neurosci 262(7):557-564. doi:10.1007/s00406-012-0302-2
10. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S (2010) Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res 175(1-2):47-53. doi:10.1016/j.psychres.2009.01.013
11. Bicikova M, Hampl R, Hill M, Ripova D, Mohr P, Putz Z (2011) Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuro Endocrinol Letters 32(2):141-147
12. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11(2):143-149. doi:10.1038/sj.mp.4001746
13. Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, Tomotake M, Ohi K, Hashimoto R, Imoto I, Takeda M, Ohmori T (2014) Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull. doi:10.1093/schbul/sbt154
14. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 94(11):5923-5928
15. Misiak B, Frydecka D, Piotrowski P, Kiejna A (2013) The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation. Epigenomics 5(3):317-329. doi:10.2217/epi.13.22
16. Dempster E, Viana J, Pidsley R, Mill J (2013) Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future. Schizophr Bull 39(1):11-16. doi:10.1093/schbul/sbs139
17. Nishioka M, Bundo M, Kasai K, Iwamoto K (2012) DNA methylation in schizophrenia: progress and challenges of epigenetic studies. Genome Med 4(12):96. doi:10.1186/gm397
18. Geller V, Friger M, Sela BA, Levine J (2013) Elevated homocysteine level in siblings of patients with schizophrenia. Psychiatry Res 210(3):769-772. doi:10.1016/j.psychres.2013.08.016
19. Roffeei SN, Mohamed Z, Reynolds GP, Said MA, Hatim A, Mohamed EH, Aida SA, Zainal NZ (2014) Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics 15(4):477-485. doi:10.2217/pgs.13.220
20. Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zollner SK, Pop-Busui R (2012) Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol 32(2):261-265. doi:10.1097/JCP.0b013e3182485888
21. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M (2010) MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 121(1-3):193-198. doi:10.1016/j.schres.2010.05.030
22. van Winkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, van Os J, De Hert M (2010) MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int Clin Psychopharmacol 25(5):270-276. doi:10.1097/YIC.0b013e32833bc60d
23. Srisawat U, Reynolds GP, Zhang ZJ, Zhang XR, Arranz B, San L, Dalton CF (2013) Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. Int J Neuropsychopharmacol:1-6. doi:10.1017/S1461145713001375
24. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J (2008) Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 98(1-3):47-54. doi:10.1016/j.schres.2007.09.030
25. McGuffin P, Farmer A, Harvey I (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system Archives of general psychiatry 48(8):764-770
26. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261-276
27. Pomerleau CS, Majchrzak MJ, Pomerleau OF (1989) Nicotine dependence and the Fagerstrom tolerance questionnaire: a brief review. J Subst Abus 1(4):471-477
28. Eren E, Yegin A, Yilmaz N, Herken H (2010) Serum total homocystein, folate and vitamin B12 levels and their correlation with antipsychotic drug doses in adult male patients with chronic schizophrenia. Clinical Laboratory 56(11-12):513-518
29. Lu ML, Lin CH, Chen YC, Yang HC, Wu TH (2013) Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters. PLoS One 8(5):e65719. doi:10.1371/journal.pone.0065719
30. Vuksan-Cusa B, Sagud M, Jakovljevic M, Peles AM, Jaksic N, Mihaljevic S, Zivkovic M, Mikulic SK, Jevtovic S (2013) Association between C-reactive protein and homocysteine with the subcomponents ofmetabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nordic J Psychiatr 67(5):320-325. doi:10.3109/08039488.2012.745601
31. Vuksan-Cusa B, Jakovljevic M, Sagud M, Mihaljevic Peles A, Marcinko D, Topic R, Mihaljevic S, Sertic J (2011) Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Psychiatry Res 189(1):21-25. doi:10.1016/j.psychres.2010.11.021
32. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690):620-627. doi:10.1016/S0140-6736(09)60742-X
33. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S (2011) Risperidone versus other atypical antipsychotics for schizophrenia. The Cochrane Database of Systematic Reviews 1, CD006626. doi:10.1002/14651858.CD006626.pub2
34. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA (2009) Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 111(1-3):9-16. doi:10.1016/j.schres.2009.03.025
35. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL (2007) A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. The J Clin Psychiatry 68(11):1733-1740
36. Perez-Iglesias R, Martinez-Garcia O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, Crespo-Facorro B (2014) Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 17(1):41-51. doi:10.1017/S1461145713001053
37. Melka MG, Laufer BI, McDonald P, Castellani CA, Rajakumar N, O'Reilly R, Singh SM (2014) The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum. Clin Epigenetics 6(1):1. doi:10.1186/1868-7083-6-1
38. Sarandol A, Kirli S, Akkaya C, Ocak N, Eroz E, Sarandol E (2007) Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment. J Psychopharmacol 21(8):857-863. doi:10.1177/0269881107077609
39. Petronijevic ND, Radonjic NV, Ivkovic MD, Marinkovic D, Piperski VD, Duricic BM, Paunovic VR (2008) Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 32(8):1921-1926. doi:10.1016/j.pnpbp.2008.09.009
40. Wysokinski A, Kloszewska I (2013) Homocysteine levels in patients with schizophrenia on clozapine monotherapy. Neurochem Res 38(10):2056-2062. doi:10.1007/s11064-013-1113-1
41. Yakub M, Moti N, Parveen S, Chaudhry B, Azam I, Iqbal MP (2012) Polymorphisms in MTHFR, MS and CBS genes and homocysteine levels in a Pakistani population. PLoSOne 7(3):e33222. doi:10.1371/journal.pone.0033222
42. Bouaziz N, Ayedi I, Sidhom O, Kallel A, Rafrafi R, Jomaa R, Melki W, Feki M, Kaabechi N, El Hechmi Z (2010) Plasma homocysteine in schizophrenia: determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res 179(1):24-29. doi:10.1016/j.psychres.2010.04.008
43. Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U (2005) Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162(9):1738-1740. doi:10.1176/appi.ajp.162.9.1738
44. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J (2004) Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 161(9):1705-1708. doi:10.1176/appi.ajp.161.9.1705
45. Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC (2013) Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 39(2):330-338. doi:10.1093/schbul/sbr150
46. Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Bottiglieri T, Wong DH, Halsted CH, Goff DC (2008) Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 63(1):42-48. doi:10.1016/j.biopsych.2006.12.017
47. Chue P, Lalonde JK (2014) Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatr Dis Treat 10:777-789. doi:10.2147/NDT.S43404
48. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S (2013) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37(8):1680-1691. doi:10.1016/j.neubiorev.2013.06.001
49. Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC (2011) Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophrenia research 127 (1-3):41-45. doi:10.1016/j.schres.2010.12.006
50. Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC (2013) Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 70(5):481-489. doi:10.1001/jamapsychiatry.2013.900
51. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH (2002) Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159(10):1790-1792
52. Applebaum J, Shimon H, Sela BA, Belmaker RH, Levine J (2004) Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res 38(4):413-416. doi:10.1016/j.jpsychires.2004.01.003
53. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B (1994) Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 236(6):633-641
54. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G (1995) Total plasma homocysteine and cardiovascular risk profile the hordaland homocysteine study JAMA. J Am Med Assoc 274(19):1526-1533
55. Gooren LJ, Giltay EJ (2008) Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sexual Medicine 5(4):765-776. doi:10.1111/j.1743-6109.2007.00646.x
56. Andersson A, Isaksson A, Hultberg B (1992) Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem 38(7):1311-1315